Skip to main content
Toggle navigation
Login
Search
Home
Tweets by ASCPT 2023 Annual Meeting
Systems Pharmacology (SP)
Home
Systems Pharmacology (SP)
Systems Pharmacology (SP)
Type here to filter the list
LB-015 - A TRANSLATIONAL COMPUTATIONAL MODEL OF ALLERGEN CHALLENGE TO SUPPORT THE CLINICAL DEVELOPMENT OF AN INTRANASALLY ADMINISTERED BACTERIAL LYSATE IN MILD ASTHMA.
Favorite
LB-016 - EFFECTIVENESS OF HIGH DOSE VERSUS STANDARD DOSE INFLUENZA VACCINES IN OLDER ADULTS : INSIGHTS FROM A MULTI-STRAIN MODELING APPROACH TAKING ANTIGENIC DISTANCE INTO ACCOUNT.
Favorite
PI-093 - A COMPREHENSIVE MIDD APPROACH TO ASSESS THE SAFETY AND EFFICACY OF TARGETED-THORIUM-CONJUGATES IN PATIENTS FOR EARLY DECISION MAKING.
Favorite
PI-094 - A QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL OF SEPSIS-INDUCED AUGMENTED RENAL CLEARANCE.
Favorite
PI-095 - BLINATUMOMAB TRIMER FORMATION - INSIGHTS FROM A MECHANISTIC PKPD MODEL ON THE IMPLICATIONS FOR SWITCHING FROM INFUSION TO SUBCUTANEOUS DOSING REGIMEN IN ACUTE LYMPHOBLASTIC LEUKEMIA AND NON-HODGKIN’S LYMPHOMA.
Favorite
PI-096 - DEVELOPMENT OF IMMUNO-ONCOLOGY (IO) QSP PLATFORM MODEL FOR EFFICACY PREDICTION OF CHECKPOINT INHIBITORS (CPI) AND ADC COMBINATION THERAPY IN PHASE II/III CLINICAL TRIALS.
Favorite
PII-123 - A MODEL-BASED META-ANALYSIS TO ASSESS THE SIMILARITIES AND DIFFERENCES OF CLINICAL SAFETY OF TARGETED-THORIUM-CONJUGATES IN PATIENTS.
Favorite
PII-124 - APPLICATION OF MACHINE LEARNING (ML) ON QSP VIRTUAL PATIENT POPULATION (VPOP) FOR IDENTIFICATION OF BIOMARKERS OF RESPONSE AND FOR SELECTION OF PRE-CONDITIONING REGIMEN FOR ENGINEERED T-CELL (ET-CELL) THERAPY.
Favorite
PII-125 - DEVELOPMENT OF RHEUMATOID ARTHRITIS QSP MODEL FOR TRIAL SIMULATION AND PREDICTING RESPONSE TO NOVEL COMBINATIONS.
Favorite
PII-126 - QUANTITATIVE SYSTEMS TOXICOLOGY (QST) MODELING USING DILISYM INFORMED SAFE DOSE SELECTION OF EMVODODSTAT IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS.
Favorite
PWII-005 - APPLICATION OF MACHINE LEARNING (ML) ON QSP VIRTUAL PATIENT POPULATION (VPOP) FOR IDENTIFICATION OF BIOMARKERS OF RESPONSE AND FOR SELECTION OF PRE-CONDITIONING REGIMEN FOR ENGINEERED T-CELL (ET-CELL) THERAPY.
Favorite
